Therapeutic vaccines for leishmaniasis

Expert Opinion on Biological Therapy

Volumn 14, Issue 11, 2014, Pages 1641-1649

  Khamesipour, Ali ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Leishmaniasis immunotherapy; Treatment of leishmaniasis; Vaccine against leishmaniasis

Indexed keywords

IMMUNOMODULATING AGENT; LEISHMANIA VACCINE; MEGLUMINE ANTIMONATE; STIBOGLUCONATE SODIUM; IMMUNOLOGIC FACTOR; IMMUNOLOGICAL ADJUVANT;

HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; LABORATORY DIAGNOSIS; LEISHMANIASIS; MUCOCUTANEOUS LEISHMANIASIS; REVIEW; SKIN LEISHMANIASIS; TREATMENT OUTCOME; VACCINATION; VISCERAL LEISHMANIASIS; ANIMAL; LEISHMANIASIS, CUTANEOUS; PROCEDURES; TRENDS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; LEISHMANIASIS; LEISHMANIASIS VACCINES; LEISHMANIASIS, CUTANEOUS;

EID: 84911051071     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2014.945415     Document Type: Review

References (64)

1. Alvar J, Velez ID, Bern C, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 2012;7(5):e35671
2. Akilov OE, Khachemoune A, Hasan T. Clinical manifestations and classification of Old World cutaneous leishmaniasis. Int J Dermatol 2007;46(2):132-42
3. Gontijo B, de Carvalho Mde L. American cutaneous leishmaniasis. Rev Soc Bras Med Trop 2003;36(1):71-80
4. Bonfante-Garrido R, Barroeta S, de Alejos MA, et al. Disseminated American cutaneous leishmaniasis. Int J Dermatol 1996;35(8):561-5.
5. Das A, Ali N. Vaccine prospects of killed but metabolically active Leishmania against visceral leishmaniasis. Expert Rev Vaccines 2012;11(7):783-5.
6. Goto H, Prianti M. Immunoactivation and immunopathogeny during active visceral leishmaniasis. Rev Inst Med Trop Sao Paulo 2009;51(5):241-6.
7. Khalil EA, El Hassan AM, Zijlstra EE, et al. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet 2000;356(9241):1565-9.
8. Nagill R, Kaur S. Vaccine candidates for leishmaniasis: a review. Int Immunopharmacol 2011;11(10):1464-88.
9. WHO. Post-kala-azar dermal leishmaniasis: a manual for case management and control. report of a who consultative meeting. Kolkata, India; 2012 Available from: http://apps.who.int/iris/bitstream/10665/78608/1/9789241505215-eng.pdf.
10. Goto H, Lindoso JA. Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev Anti Infect Ther 2010;8(4):419-33.
11. Barroso PA, Marco JD, Calvopina M, et al. A trial of immunotherapy against Leishmania amazonensis infection in vitro and in vivo with Z-100, a polysaccharide obtained from Mycobacterium tuberculosis, alone or combined with meglumine antimoniate. J Antimicrob Chemother 2007;59(6):1123-9.
12. Croft SL, Olliaro P. Leishmaniasis chemotherapy-challenges and opportunities. Clin Microbiol Infect 2011;17(10):1478-83
13. Firooz A, Khamesipour A, Ghoorchi MH, et al. Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial. Arch Dermatol 2006;142(12):1575-9
14. Khatami A, Firooz A, Gorouhi F, et al. Systematic review of new world cutaneous leishmaniasis: several points. Int J Dermatol 2009;48(2):201; author reply 201-2.
15. Bumb RA, Prasad N, Aara N, et al. Long-term efficacy of a single-dose Radio Frequency Heat therapy versus intralesional antimonials for cutaneous leishmaniasis in India. Br J Dermatol 2013;168(5):1114-19.
16. Sacks D, Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2002;2(11):845-58
17. Bogdan C. Leishmaniasis in rheumatology, haematology and oncology: epidemiological, immunological and clinical aspects and caveats. Ann Rheum Dis 2012;71(Suppl 2):i60-6
18. Peters NC, Egen JG, Secundino N, et al. In vivo imaging reveals an essential role for neutrophils in leishmaniasis transmitted by sand flies. Science 2008;321(5891):970-4
19. Habibi GR, Khamesipour A, McMaster WR, et al. Cytokine gene expression in healing and non-healing cases of cutaneous leishmaniasis in response to in vitro stimulation with recombinant gp63 using semi-quantitative RT-PCR. Scand J Immunol 2001;54(4):414-20
20. Hejazi SH, Hoseini S, Javanmard SH, et al. Interleukin-10 and transforming growth factor-beta in early and late lesions of patients with leishmania major induced cutaneous leishmaniasis. Iran J Parasitol 2012;7(3):16-23
21. Hoseini SG, Javanmard SH, Zarkesh SH, et al. Regulatory T-cell profile in early and late lesions of cutaneous leishmaniasis due to Leishmania major. J Res Med Sci 2012;17(6):513-18
22. Jafari-Shakib R, Ajdary S, Amiri ZM, et al. CD26 expression on CD4+T cells in patients with cutaneous leishmaniasis. Clin Exp Immunol 2008;153(1):31-6.
23. Khamesipour A, Dowlati Y, Asilian A, et al. Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis. Vaccine 2005;23(28):3642-8.
24. Mahmoodi M, Khamesipour A, Dowlati Y, et al. Immune response measured in human volunteers vaccinated with autoclaved Leishmania major vaccine mixed with low dose of BCG. Clin Exp Immunol 2003;134(2):303-8.
25. Nateghi Rostami M, Keshavarz H, Edalat R, et al. CD8+ T cells as a source of IFN-gamma production in human cutaneous leishmaniasis. PLoS Negl Trop Dis 2010;4(10):e845
26. Tolouei S, Ghaedi K, Khamesipour A, et al. IL-23 and IL-27 levels in macrophages collected from peripheral blood of patients with healing vs non-healing form of cutaneous leishmaniasis. Iran J Parasitol 2012;7(1):18-25
27. Nateghi Rostami M, Keshavarz Valian H, Eskandari SE, et al. Differential in vitro CD4+/CD8+ T-cell response to live vs. killed Leishmania major. Parasite Immunol 2010;32(2):101-10.
28. Noazin S, Khamesipour A, Moulton LH, et al. Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis: a meta-analysis. Vaccine 2009;27(35):4747-53.
29. Duthie MS, Vanitha RS, Franco PM, et al. The development and clinical evaluation of second-generation leishmaniasis vaccines. Vaccine 2012;30(2):134-41.
30. Singh B, Sundar S. Leishmaniasis: vaccine candidates and perspectives. Vaccine 2012;30(26):3834-42.
31. Badiee A, Jaafari MR, Samiei A, et al. Coencapsulation of CpG oligodeoxynucleotides with recombinant Leishmania major stress-inducible protein 1 in liposome enhances immune response and protection against leishmaniasis in immunized BALB/c mice. Clin Vaccine Immunol 2008;15(4):668-74
32. Firouzmand H, Badiee A, Khamesipour A, et al. Induction of protection against leishmaniasis in susceptible BALB/c mice using simple DOTAP cationic nanoliposomes containing soluble Leishmania antigen (SLA). Acta Trop 2013;128(3):528-35.
33. Momeni AZ, Jalayer T, Emamjomeh M, et al. A randomized, double blind, controlled trial of a killed L. major vaccine plus BCG against ZCL in Iran. Vaccine 1999;17:466-72
34. Sharifi I, Fekri A, Aflatonian M, et al. Double-blind randomized controlled vaccine trial of a single dose of killed Leishmania major plus Bacillus of Calmette Guerin (BCG) against anthroponotic cutaneous Leishmaniasis Bam, Iran. Lancet 1998.
35. Alvar J, Croft SL, Kaye P, et al. Case study for a vaccine against leishmaniasis. Vaccine 2013;31(Suppl 2):B244-9.
36. Badiee A, Heravi Shargh V, Khamesipour A, et al. Micro/nanoparticle adjuvants for antileishmanial vaccines: present and future trends. Vaccine 2013;31(5):735-49.
37. Okwor I, Uzonna JE. As a strategy for treatment of leishmaniasis: a review of the literature. Immunotherapy 2009;1(5):765-76.
38. Simon J. Emil Behring's medical culture: from disinfection to serotherapy. Med Hist 2007;51(2):201-18.
39. Chakravarty J, Kumar S, Trivedi S, et al. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1 +MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine 2011;29(19):3531-7.
40. Waldmann TA. Immunotherapy: past, present and future. Nat Med 2003;9:269-77.
41. Pennington JE. Immunotherapy of infectious diseases: past, present and future. Trans Am Clin Climatol Assoc 1988;99:126-35.
42. Luke TC, Arturo C, Stanley WJ, et al. Hark back: passive immunotherapy for influenza and other serious infections. Crit Care Med 2010;38:e66-73.
43. Okwora I, Liua D, Beverley SM, et al. Inoculation of killed Leishmania major into immune mice rapidly disrupts immunity to a secondary challenge via IL-10-mediated process. Proc Natl Acad Sci USA 2009;106(33):13951-6.
44. Machado-Pinto J, Pinto J, da Costa CA, et al. Immunochemotherapy for cutaneous leishmaniasis: a controlled trial using killed Leishmania (Leishmanin amazonensis vaccine plus antimonial. Int J Dermatol 2002;41(2):73-8
45. Toledo VP, Mayrink W, Gollob KJ, et al. Immunochemotherapy in American cutaneous leishmaniasis: immunological aspects before and after treatment. Mem Inst Oswaldo Cruz 2001;96(1):89-98
46. Mayrink W, Botelho AC, Magalhaes PA, et al. Immunotherapy, immunochemotherapy and chemotherapy for American cutaneous leishmaniasis treatment. Rev Soc Bras Med Trop 2006;39(1):14-21
47. Convit J, Ulrich M, Zerpa O, et al. Immunotherapy of American cutaneous leishmaniasis in Venezuela during the period 1990--1999. Trans R Soc Trop Med Hyg 2003;97:469-72
48. Cabrera M, Blackwell JM, Castes M, et al. Immunotherapy with live BCG plus heat killed Leishmania induces a T helper 1-like response in American cutaneous leishmaniasis patients. Parasite Immunol 2000;22(2):73-9
49. Convit J, Ulrich M, Polegre MA, et al. Therapy of Venezuelan patients with severe mucocutaneous or early lesions of diffuse cutaneous leishmaniasis with a vaccine containing pasteurized Leishmania promastigotes and bacillus Calmette-Guerin: preliminary report. Mem Inst Oswaldo Cruz 2004;99(1):57-62
50. O'Daly JA, Spinetti HM, Gleason J, et al. Clinical and immunological analysis of cutaneous leishmaniasis before and after different treatments. J Parasitol Res 2013;2013:657016
51. Khalil EA, Musa AM, Modabber F, et al. Safety and immunogenicity of a candidate vaccine for visceral leishmaniasis (Alum-precipitated autoclaved Leishmania major + BCG) in children: an extended phase II study. Ann Trop Paediatr 2006;26(4):357-61.
52. Musa AM, Khalil EA, Mahgoub FA, et al. Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment. Trans R Soc Trop Med Hyg 2008;102(1):58-63.
53. Modabber F. Leishmaniasis vaccines: past, present and future. PLoS Negl Trop Dis 2010;36(Suppl 1):S51-61.
54. Badaro R, Lobo I, Munos A, et al. Immunotherapy for drug-refractory mucosal leishmaniasis. J Infect Dis 2006;194(8):1151-9.
55. Nascimento E, Fernandes DF, Vieira EP, et al. Vaccination of humans against cutaneous leishmaniasis: cellular and humoral immune responses. Infect Immun 1990;58(7):2198-203.
56. Awasthi A, Mathur RK, Saha B. Immune response to Leishmania infection. Indian J Med Res 2004;119(6):238-58.
57. Beattie L, Kaye PM. Leishmania-host interactions: what has imaging taught us? Cell Microbiol 2011;13(11):1659-67
58. Bogdan C. Natural killer cells in experimental and human leishmaniasis. Front Cell Infect Microbiol 2012;2:69
59. De Almeida Silva L, Romero HD, Prata A, et al. Immunologic tests in patients after clinical cure of visceral leishmaniasis. Am J Trop Med Hyg 2006;75(4):739-43
60. Gaafar A, el Kadaro AY, Theander TG, et al. The pathology of cutaneous leishmaniasis due to Leishmania major in Sudan. Am J Trop Med Hyg 1995;52(5):438-42
61. Kaye PM, Aebischer T. Visceral leishmaniasis: immunology and prospects for a vaccine. Clin Microbiol Infect 2011;17(10):1462-70.
62. Musa AM, Noazin S, Khalil EA, et al. Immunological stimulation for the treatment of leishmaniasis: a modality worthy of serious consideration. Trans R Soc Trop Med Hyg 2010;104(1):1-2.
63. Nylen S, Gautam S. Immunological perspectives of leishmaniasis. J Glob Infect Dis 2010;2(2):135-46.
64. Evans KJ, Kedzierski L. Development of vaccines against visceral leishmaniasis. J Trop Med 2012;2012:892817.